© Hookipa Biotech
A vaccination against the Cytomegalovirus ("CMV"), which is a herpesvirus, should be tested on patients undergoing organ transplants. In addition, immunization therapy is to be tested on patients with head and neck squamous cell carcinoma. Founded in 2011, the company develops active immunotherapies against cancer and infectious diseases. The new investors include a blue-chip U.S. public investment fund as well as HBM Partners, Hillhouse Capital, Sirona Capital and the strategic investor Gilead. The existing investors of Hookipa, namely Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners, also participated in the financing. An infection with CMV is harmless for healthy people, but can be deadly for people with weakened immune systems, especially following organ transplants. An infection during pregnancy can also have fatal consequences for the baby.Founded in 2011, the company develops active immunotherapies against cancer and infectious diseases. The new investors include a blue-chip U.S. public investment fund as well as HBM Partners, Hillhouse Capital, Sirona Capital and the strategic investor Gilead. The existing investors of Hookipa, namely Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners, also participated in the financing. An infection with CMV is harmless for healthy people, but can be deadly for people with weakened immune systems, especially following organ transplants. An infection during pregnancy can also have fatal consequences for the baby.
